Investment Gaps in AMR R&D: New Analysis Highlights Strategic Opportunities
Our article in the European Journal of Health Economics investigates the landscape of antimicrobial resistance (AMR) research and development investments across Europe 2017–2021. The analysis—leveraging data from the Hub’s Dynamic Dashboard—offers critical insights:
-
Substantial funding focuses on human health, with limited resources allocated to animal, environmental, and plant-related AMR research, and a focus on bacterial pathogens
-
Investment is heavily concentrated among a few countries
By quantifying these gaps across One Health sectors, pathogens, and funding sources, the study equips policymakers and funders with data-driven insights to prioritize underfunded R&D areas and maximize impact.
Read the full analysis here: Explore investment imbalances across sectors, infectious agents, and economies to guide smarter, evidence-based AMR investments.
